UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

__________________________________

FORM 6-K

__________________________________

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 30, 2024

Commission File Number 001-38332

QIAGEN N.V.

Hulsterweg 82

5912 PL Venlo

The Netherlands

__________________________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F x           Form 40-F  o

QIAGEN N.V.

Form 6-K

Table of Contents

Item	Page
Other Information	3
Signatures	4
Exhibit Index	5

2

Other Information

On June 6, 2024, QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) issued a press release with details about the decision to discontinue the NeuMoDx 96 and 288 Molecular Systems. The press release is furnished herewith as Exhibit 99.1 and is incorporated by reference herein.

3

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	QIAGEN N.V.
By:	/s/ Roland Sackers
	Roland Sackers
	Chief Financial Officer
Date:	June 6, 2024

4

Exhibit Index

Exhibit No.	Exhibit
99.1	Press Release dated June 6, 2024

5